AR042035A1 - Uso de rmlt como antigeno marcador para vacunas y como un aditivo sinergico con amphigen - Google Patents

Uso de rmlt como antigeno marcador para vacunas y como un aditivo sinergico con amphigen

Info

Publication number
AR042035A1
AR042035A1 ARP030104169A ARP030104169A AR042035A1 AR 042035 A1 AR042035 A1 AR 042035A1 AR P030104169 A ARP030104169 A AR P030104169A AR P030104169 A ARP030104169 A AR P030104169A AR 042035 A1 AR042035 A1 AR 042035A1
Authority
AR
Argentina
Prior art keywords
rmlt
animal
vaccine composition
immunogen
toxic
Prior art date
Application number
ARP030104169A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR042035A1 publication Critical patent/AR042035A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56933—Mycoplasma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Métodos que permiten a los propietarios de animales o a los productos de alimentos para animales establecer fácilmente el estado de vacunación de los animales. Más específicamente, la presente invención proporciona un método para identificar un animal que se ha vacunado con un inmunógeno formando una composición vacunal que incluye el inmunógeno y una enterotoxina termolábil de E. Coli mutante, prácticamente atóxica (rmLT); administrando la composición vacunal a sujetos animales; y detectando la presencia de anticuerpos o células inmunitarias en un animal, que sean específicas para la rmLT, como indicativo de una vacunación anterior del animal con dicha preparación vacunal. Método para determinar si un animal se ha vacunado con una composición vacunal que incluye un inmunógeno y una rmLT prácticamente atóxica, detectando la presencia de anticuerpos o células inmunitarias en un animal que sean específicas para la rmLT, como indicativo de una vacunación anterior del animal con dicha preparación vacunal. Método para marcar o identificar una composición vacunal, incluyendo en la composición vacunal una rmLT prácticamente atóxica y detectando la presencia de anticuerpos o células inmunitarias en animales a los que se les ha administrado tal composición vacunal. Método para incrementar los efectos inmunoprotectores de un inmunógeno en una composicion vacunal, incluyendo la composición vacunal una rmLT prácticamente atóxica. También se proporcionan composiciones vacunales que contienen un inmunógeno, una rmLT prácticamente atóxica y un aditivo de emulsión de aceite en agua como AMPHIGEN(R ).
ARP030104169A 2002-11-14 2003-11-12 Uso de rmlt como antigeno marcador para vacunas y como un aditivo sinergico con amphigen AR042035A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42642102P 2002-11-14 2002-11-14

Publications (1)

Publication Number Publication Date
AR042035A1 true AR042035A1 (es) 2005-06-08

Family

ID=32313133

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030104169A AR042035A1 (es) 2002-11-14 2003-11-12 Uso de rmlt como antigeno marcador para vacunas y como un aditivo sinergico con amphigen

Country Status (9)

Country Link
US (1) US20040170637A1 (es)
EP (1) EP1581256A4 (es)
JP (1) JP2006506615A (es)
AR (1) AR042035A1 (es)
AU (1) AU2003278496A1 (es)
CL (1) CL2003002326A1 (es)
TW (1) TW200420298A (es)
UY (1) UY28082A1 (es)
WO (1) WO2004043286A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090110698A1 (en) * 2007-10-31 2009-04-30 Newport Laboratories, Inc. Method of determining vaccine compliance
MX362166B (es) * 2012-03-07 2018-12-14 Ceva Sante Animale Nueva vacuna veterinaria.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2849632B2 (ja) * 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
IT1253009B (it) * 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
US5955342A (en) * 1994-08-15 1999-09-21 Connaught Laboratories Limited Non-infectious, replication-defective, self-assembling HIV-1 viral particles containing antigenic markers in the gag coding region
US6436407B1 (en) * 1994-08-26 2002-08-20 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic adjuvant
US6019982A (en) * 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
DE19643682C1 (de) * 1996-10-23 1998-01-15 Manfred Prof Dr Gareis Verfahren zum Herkunftsnachweis von Nutztieren sowie davon stammenden Produkten
US6033673A (en) * 1998-03-18 2000-03-07 The Administrators Of Tulane Educational Fund Double mutant enterotoxin for use as an adjuvant
DE19847118C2 (de) * 1998-10-13 2000-09-07 November Ag Molekulare Medizin Verfahren und Verwendung zur Markierung und Identifizierung applizierter Mittel

Also Published As

Publication number Publication date
WO2004043286A2 (en) 2004-05-27
JP2006506615A (ja) 2006-02-23
EP1581256A2 (en) 2005-10-05
EP1581256A4 (en) 2006-06-07
WO2004043286A3 (en) 2004-09-30
US20040170637A1 (en) 2004-09-02
TW200420298A (en) 2004-10-16
AU2003278496A1 (en) 2004-06-03
AU2003278496A8 (en) 2004-06-03
CL2003002326A1 (es) 2005-04-01
UY28082A1 (es) 2004-06-30

Similar Documents

Publication Publication Date Title
Meeusen et al. Current status of veterinary vaccines
Kreiss et al. Evidence for induction of humoral and cytotoxic immune responses against devil facial tumor disease cells in Tasmanian devils (Sarcophilus harrisii) immunized with killed cell preparations
BRPI0510430A (pt) composições e métodos para vacinação mucosal
TW200744631A (en) Lawsonia vaccine and methods of use thereof
CO5611162A2 (es) Metodos para prevenir enfermedades reproductivas en el ganado vacuno
CR7742A (es) Formulaciones para uso veterinario que contienen productos de origen no animal
ES2118815T3 (es) Virus de la seudorrabia, s-prv-155, atenuado y obtenido por ingenieria genetica y sus usos.
NO20082472L (no) Vaksinesammensetninger omfattende en saponin adjuvant
MX2009006178A (es) Vacuna contra salmonela.
CY1120430T1 (el) Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων
Lafontaine et al. The autotransporter protein BatA is a protective antigen against lethal aerosol infection with Burkholderia mallei and Burkholderia pseudomallei
JP2023145596A5 (es)
ATE310008T1 (de) Immunologische adjuvans verbindungen
Pecora et al. Development of an enhanced bovine viral diarrhea virus subunit vaccine based on E2 glycoprotein fused to a single chain antibody which targets to antigen-presenting cells
AR042035A1 (es) Uso de rmlt como antigeno marcador para vacunas y como un aditivo sinergico con amphigen
AR059648A1 (es) Antigenos vacunales quimericos contra el virus de la peste porcina clasica
ES2828873T3 (es) Vacuna contra la disentería porcina
PT2050463E (pt) Composição de vacina para vacinar cães contra a doença respiratória infeciosa canina (cird)
HUP0104125A2 (hu) Eljárás szárnyasok intradermális immunizálására inaktivált vakcinákkal
RU2010143584A (ru) Вакцина для защиты от haemophilus parasuis серотипа 4 у поросят
CY1113746T1 (el) Εμβολιο που περιλαμβανει ανοσοενισχυτικο γαλακτωμα ελαιου σε υδωρ
WO2004100640A3 (en) Marek’s disease virus vaccine
US20220040289A1 (en) Rabies Composition Comprising Pika Adjuvant
AR111910A2 (es) Composición inmunogénica que comprende una formulación de adyuvante, composición de vacuna, procedimiento, usos, métodos
BR112017004703A2 (pt) ?vacina e método para proteção de progênie de uma porca contra infeccção por um vírus de diarreia endêmica suína?

Legal Events

Date Code Title Description
FB Suspension of granting procedure